Ascentage Pharma Group
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ascentage Pharma Group sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Ascentage Pharma Group: 15 sponsored US clinical trials, 8 recruiting.
Ascentage Pharma Group sponsors 15 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting, and 4 completed. 4 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is CLL/SLL, with 2 trials.
Top-decile sponsor footprint
Ascentage Pharma Group ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
15 total, page 1 of 1
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
NCT06641414
Study of Olverembatinib (HQP1351) in Patients With CP-CML
NCT06423911
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
NCT04496349
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
NCT04215809
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
NCT04260022
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
NCT03537482
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
NCT03611868
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
NCT07424833
APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia
NCT04260217
Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
NCT04210037
APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies
NCT03386526
A Study of APG-1252 in Patients With SCLC or Other Solid Tumors
NCT03080311
APG-115 in Patients With Advanced Solid Tumors or Lymphomas
NCT02935907
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 1 |
| Phase 3 | 4 |
Therapeutic Areas
What is open in the Ascentage Pharma Group pipeline
8 recruiting of 15 indexed (53% open); 4 completed (27%).
Phase mix: 4 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: CLL/SLL (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ascentage Pharma Group: open-pipeline peers nationwide
Peers matched on 15 registered trials and 53% open enrollment, not the therapeutic-area sidebar.
Ascentage Pharma Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 trials (± recruiting share)
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors near 53% open enrollment (± trial volume)
- Children's Hospital of Orange County · 54% recruiting · 13 trials
- University of Notre Dame · 54% recruiting · 13 trials
- Disc Medicine · 56% recruiting · 9 trials
- Heart Rhythm Clinical and Research Solutions · 56% recruiting · 9 trials
Related
What to do with this Ascentage Pharma Group page
15 registered trials is a research-attention snapshot, not an endorsement of Ascentage Pharma Group or any single study.
- 8 of Ascentage Pharma Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- CLL/SLL is the condition Ascentage Pharma Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See CLL/SLL trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Ascentage Pharma Group pipeline card: 15 registered trials from official public datasets.Report a data error.